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Analgesic efficacy of APS (Action
Potential Simulation). Pilot study
of the patients with chronic pain
due to musculoskeletal disorders
Abstract
Background and aims. Pain in musculoskeletal disorders is common medical problem, however frequently
difficult to treat. That is why different methods of physical therapies have been tried with the controversial
results. APS-therapy (Action Potential Simulation) falls under the broad definition of MET (Microcurrent
Electrical Stimulation). MET may be a useful treatment for many pain-related disorders, providing fast relief
of symptoms. The aim of this pilot clinical study was to investigate the analgesic efficacy of APS-
-therapy in chronic pain due to musculoskeletal disorders.
Methods. The study involved 12 patients with musculoskeletal disorders who suffered from chronic pain.
Each patient received treatment for 3 weeks time. APS-therapy was administered for a period of
16 minutes, 5 times a week. Treatment was given by portable unit, that generated an APS waveform (monophasic,
pulse width 800 ms, frequency 150 Hz and intensity 0.51.5 mA). NRS (Numerical Rating Scale) evaluation
was performed for 3 days of pre-treatment period, before each treatment which reflected the pain situation
of the previous 24 h, and once daily for 2 weeks after treatment.
Results. The initial mean NRS in pre-treatment period was 5.53 (SD = 1.94), decreased after APS-therapy to
3.45 (SD = 1.4) (p = 0.002) and even more to 2.56 (SD = 1.23) in the post-treatment period (p = 0.0003).
Mean pain intensity decreased significantly after 11 sessions and remained on the same level up to 2 weeks
of post-treatment observation.
Conclusion. APS-therapy may be an effective method of nonpharmacological treatment of chronic pain in
muscoskeletal disorders.
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Introduction
Electrotherapy is useful for treating a variety of
clinical conditions. Indeed, it may be the main or
complementary method for treating many pain re-
lated disorders, providing fast relief of symptoms.
APS-therapy (Action Potential Simulation) falls un-
der the broad definition of MET (Microcurrent Elec-
trical Stimulation). This type of electrical modality
uses an electrical current of less than 1 mA, which is
measured in the microamperage range. The APS-
-therapy produces current that is claimed to stimu-
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late an action potential in the neuron. According to
the Arndt-Schultz Law weak stimuli increase physio-
logical activity [1]. Investigation into the physiolog-
ical mechanisms involved has shown that these sub-
threshold currents cause the following effects: chang-
es in cell wall permeability, increase of the intracel-
lular concentrations of Ca2+ and adenosine triphos-
phate (ATP) production, stimulation of protein syn-
thesis and increase of fibroblast activity [2]. The APS
device was invented and designed by
G.A. Lubbe in 1991 in South Africa, and marketed in
1994 even without published studies in peer-re-
viewed journals [2]. Nowadays there is scarcity of
published literature of APS therapy. A controlled
trial using APS-therapy and TENS (Transcutaneous
Electrical Nerve Stimulation) to treat the pain of
osteoarthritis of the knee was reported by Berger
[3]. In this study electrotherapy (APS and TENS)
proved to be beneficial in the relief of stiffness and
pain, especially occurring at night [3]. Other authors
who studied the usage of APS therapy in chronic
and acute post-traumatic pain conditions (low back
pain, tennis elbow, sports injuries, shoulder pain,
arthritis) indicate that APS therapy produces 40
80% pain relief after 515 treatment sessions [47].
The aim of this pilot study was to investigate the
analgesic efficacy of APS-therapy in chronic pain
due to musculoskeletal disorders.
Methods
The study protocol was accepted by the Ethics
Committee of the Nicolaus Copernicus University,
Collegium Medicum Bydgoszcz in Poland. Before
the trial each patient was examined by the physi-
cian and signed an informed consent. The inclu-
sion and exclusion criteria are presented in the Ta-
ble 1. The study involved 12 patients with muscu-
loskeletal disorders who suffered from chronic
pain. The demographic and clinical data of inves-
tigated subjects are presented in the Table 2. Each
patient received three weeks treatment. The APS-
therapy was administered for a period of 16 min-
utes, 5 times a week. The treatment was given by
portable unit, that generated APS waveform. Tech-
nical specifications of the APS therapy device and
information about stimulation parameters and
electrodes placements are presented in the Table
3. NRS (Numerical Rating Scale) evaluation was
performed for 3 days of pre-treatment period,
before each treatment which reflected the pain
situation of the previous 24 h and once daily for
2 weeks after treatment.
On 24th day of treatment the patients were asked
to estimate the level of satisfaction in seven degrees
scale (from 3 to 3)  Satisfaction Scores.
Statistical analysis was made using a licensed
version of statistical software STATISTICA PL 5.0 for
Windows. Distribution of variables by Kolomogor-
ow-Smirnow test was abnormal, therefore non-para-
metric statistical tests were chosen. The results were
calculated as median NRS score value for respective
day of the investigation and presented in Figure 1.
Moreover, for every study phase for each subject
the mean of NRS score value was calculated. The
statistical significance of difference between values
calculated for each day of the study (Fig. 1), as well
as for every study phase (Table 4) was estimated
using one way ANOVA method with 38 repetitions
and Scheffe post hoc test. The final results were
presented as the median and 95% CI (confidence
interval).
Table 1. Patients inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients with chronic pain due to musculoskeletal disorders Cardiac pacemaker
Average pain intensity not less than 3 measured in NRS Epilepsy
Patients able to estimate pain intensity Inflamed or infected skin in planned electrodes
placement
Patients, which signed an informed consent Thrombosis in anticoagulants treatment period
Patients over 18 Pregnancy
Table 2. Patients characteristics
Total number of patients 12
Gender
Male 3
Female 9
Age (median – 95% CI) 26 – 21.940.3
Clinical diagnosis
Degenerative Joint Disease 9
Painful Shoulder Syndrome 1
Rheumatoid Arthritis 2
Medication
Anti-inflammatory 1
Analgesics 2
No medication 9
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Results
The median values of NRS score within respec-
tive days of the study were presented in Figure 1.
The effect of applied therapy was significant in esti-
mation by one-way ANOVA method [F (22.22) =
= 22.17; p < 0.001]. In comparison to NRS score
values obtained within three days of the pre-treat-
ment period, after 11 days of APS therapy pain in-
tensity significantly decreased (Table 4). The effect
of therapy was maintained for the subsequent ten
days of the APS therapy, as well as within 14 days of
post-treatment observation period (Fig. 1).
The median of the means NRS score values ob-
tained within the pre-treatment period, within 14
(21)-days long APS therapy and during 14-days long
observation period are presented in table 4. In com-
parison to the initial value, the NRS score after APS
therapy and after observation period were signifi-
cantly lower, in average by 36% and 51%, respec-
tively. Pain intensity was also significantly lower dur-
ing post-treatment observation period in compari-
Table 3. Procedure parameters
Stimulation parameters Wave form  APS Electrodes placements
Frequency = 150 Hz Two channels, electrodes were placed to
Pulse width = 800 ms surround the target area
Intensity = 0.51.5 mA
Treatment duration = 16 min
Figure 1. The intensity of pain in NRS score in following days and phases of the investigation, ANOVA; F (37.407) =
= 14.12; p < 0.001
Table 4. The medians and 95% CI of mean NRS score values observed in individuals within respective study
phases as well as the levels of improvement of NRS score values in respective phases of investigation (n = 12)
Parameter Pre-treatment period (1) APS-therapy period (2) Post-treatment period (3)
Median of mean NRS values 5.5 – 4.3 to 6.8 3.45 – 2.56 to 4.34* 2,36 – 1.77 to 3.35*#
Delta12 (median – 95%CI) 2.07 – 3.19 to 0.95
Delta13 (median – 95%CI) 2.97 – 4.21 to 1.73
Delta 23 (median – 95%CI) 0.90 – 1.27 to 0.52
Statistical significance in Scheffe post hoc, in ANOVA analysis F (2.22) = 22.17, p < 0.001); *p < 0.01 in comparison between initial values and
treatment or observation period, #p < 0.001 in comparison between APS treatment period and post-treatment observational period
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son to APS-treatment period (in average by 27%)
(Table 4).
The median of Satisfaction Score after 21-days
long APS therapy in seven degrees scale (from 3 to 3)
was 2 (95% CI 1.22.2). 11 patients found the treat-
ment satisfactory (Satisfaction Scores between 1 and
3), one patient didnt notice any changes (Satisfac-
tion Score = 0). During the treatment no side ef-
fects were observed.
Discussion
Many patients suffering from pain due to muscu-
loskeletal disorders are treated with pharmacotherapy
only. However, physical methods like electrotherapy
should be considered more frequently as a therapeu-
tic option. Our study suggests that APS-therapy can
be used as an alternative to drugs or complementary
methods for chronic pain management . We showed
that APS-therapy significantly decreased pain due to
different musculoskeletal disorders. Furthermore, this
kind of treatment is cheap and causes no side effects.
Another advantage of this method is the fact that the
treatment session takes a very short time (approxi-
mately 16 minutes once a day for 3 weeks) and in
many cases can be applied by the patient himself at
home. To compare, the TENS (transcutaneous electri-
cal nerve stimulation) takes a few hours a day [8].
Besides it is worth mentioning that on the contrary to
TENS, APS is a causal treatment of pain. Increase of
ATP generation after microcurrent stimulation in rat
skin models was reported by Cheng [9]. ATP plays an
essential role in the inter-body communication (gener-
ation of nerve impulses for communication and con-
trol purposes), muscle contraction (e.g. during walking,
breathing etc.), nerve conduction, transport, growth,
etc. That is the reason that APS therapy can be used in
pain relief, breakdown of inflammation and wound
healing.
Moreover the patients were satisfied with the
effects of the treatment what can be noticed in the
Satisfaction Scores.
Our study gives the rational reason for further
randomized controlled trials with placebo group
which should more accurately assess analgesic effi-
cacy of APS-therapy.
Conclusion
APS-therapy may be an effective method of non-
pharmacological treatment of chronic pain in mus-
culoskeletal disorders.
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